Glenn Prestwich

Founder at

SentrX Animal Care, Inc.

Health Technology

Consumer Services

Health Services

Profile

Glenn D.
Prestwich was the founder of Carbylan Therapeutics, Inc. (founded in 2005) where he served as the Chief Scientific Officer from 2005 to 2010.
He is also the founder of Clear Solutions Biotech, Inc. (founded in 1994) and SentrX Animal Care, Inc. (founded in 2006) where he currently holds the title of Senior Scientific Advisor.
Dr. Prestwich's current job(s) include being the Principal at GlycoMira LLC and a Professor at the University of Utah since 1996.
His former job(s) include being a Director at Brickell Subsidiary, Inc., Chief Scientific Officer at Glycosan BioSystems, Inc., and Chief Scientific Officer at Echelon Biosciences, Inc. (from 1997 to 2003).
Dr. Prestwich obtained a doctorate degree from Stanford University in 1974 and an undergraduate degree from the California Institute of Technology in 1970.

Glenn Prestwich active positions

Companies	Position	Start
University of Utah University of Utah Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	01/01/1996
SentrX Animal Care, Inc. SentrX Animal Care, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures veterinary products for ophthalmology & wound care	Founder	15/02/2010
GlycoMira LLC GlycoMira LLC Medical/Nursing ServicesHealth Services GlycoMira LLC is a clinical-stage biotechnology company developing mechanism-based oncology therapeutics focused on solid tumors and therapy-resistant cancers with inflammatory origins. The company is based in Salt Lake City, UT. The company's lead drug candidate, GM-1111, is an innate immune system modulator derived from naturally occurring polysaccharides that targets multiple molecular factors in the tumor microenvironment to inhibit innate immune receptor activation, reduce inflammatory signaling, tumor growth, treatment resistance, and cancer stem cell activity. Preclinical studies show GM-1111’s potential to enhance radiation therapy efficacy in head and neck cancers and mitigate radiation-induced oral mucositis.	Corporate Officer/Principal	-

All active positions of Glenn Prestwich

Former positions of Glenn Prestwich

Companies	Position	End
Echelon Biosciences, Inc. Echelon Biosciences, Inc. BiotechnologyHealth Technology Develops novel research reagents, assays and technology products for drug treatments	Chief Tech/Sci/R&D Officer	-
Clear Solutions Biotech, Inc.	Founder	01/01/2001
Brickell Subsidiary, Inc. Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company	Director/Board Member	-
Glycosan BioSystems, Inc. Glycosan BioSystems, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures, and markets formulations of a hyaluronan-based synthetic extracellular matrix	Chief Tech/Sci/R&D Officer	-
Carbylan Therapeutics, Inc. Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of molecule protease inhibitors	Founder	-

See the detail of Glenn Prestwich's experience

Training of Glenn Prestwich

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Glenn Prestwich's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	10
Carbylan Therapeutics, Inc. Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of molecule protease inhibitors	Health Technology
Glycosan BioSystems, Inc. Glycosan BioSystems, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures, and markets formulations of a hyaluronan-based synthetic extracellular matrix	Health Technology
SentrX Animal Care, Inc. SentrX Animal Care, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures veterinary products for ophthalmology & wound care	Health Technology
GlycoMira LLC GlycoMira LLC Medical/Nursing ServicesHealth Services GlycoMira LLC is a clinical-stage biotechnology company developing mechanism-based oncology therapeutics focused on solid tumors and therapy-resistant cancers with inflammatory origins. The company is based in Salt Lake City, UT. The company's lead drug candidate, GM-1111, is an innate immune system modulator derived from naturally occurring polysaccharides that targets multiple molecular factors in the tumor microenvironment to inhibit innate immune receptor activation, reduce inflammatory signaling, tumor growth, treatment resistance, and cancer stem cell activity. Preclinical studies show GM-1111’s potential to enhance radiation therapy efficacy in head and neck cancers and mitigate radiation-induced oral mucositis.	Health Services
Brickell Subsidiary, Inc. Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company	Health Technology
Stanford University Stanford University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Utah University of Utah Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Echelon Biosciences, Inc. Echelon Biosciences, Inc. BiotechnologyHealth Technology Develops novel research reagents, assays and technology products for drug treatments	Health Technology
California Institute of Technology California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Clear Solutions Biotech, Inc.